TriReme Receives FDA Approval for Expanded Matrix of Novel Glider PTCA Balloon Catheter
TriReme Medical Inc. (TMI) announced that it has received U.S. Food and Drug Administration (FDA) clearance for an expanded matrix of sizes for its unique Glider percutaneous transluminal coronary angioplasty (PTCA) balloon catheter. Glider is now approved for the treatment of lesions in the coronary vasculature in balloon diameters from 1.5 mm to 3.5 mm and in lengths from 4 mm to 20 mm.
The Glider PTCA Balloon Catheter is the world's only torqueable angioplasty balloon catheter. Combined with its unique balloon shape and state of the art tip technology, the Glider is designed to cross through tight lesions and stent struts even in conditions where other balloons are challenged. The unique design of the Glider provides physicians with a tool in managing the treatment of a broad range of complex lesions such as bifurcations and tight stenoses.
For more information: www.trirememedical.com